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EDITORIALGranulocyte-Macrophage Colony-Stimulating Factor-Activated
Monocytes as an Anti-inﬂammatory Player in the Intestinen the present issue of Cellular and Molecular Gastro-
1I enterology and Hepatology, Weinhage et al report on
how granulocyte-macrophage colony-stimulating factor
(GM-CSF)-activated monocytes can modulate the severity of
intestinal inﬂammation, as shown using various mouse
models of chronic colitis. As the authors point out, blood
monocytes are the source of macrophages and dendritic
cells (DCs) in the intestinal mucosa, and were previously
reported to play key roles in the pathogenesis of Crohn’s
disease.2,3 Based on this, any therapeutic approach aimed at
modulating this key player in innate immunity could be a
potent way to modulate/manage intestinal inﬂammation in
patients with chronic intestinal inﬂammation.
For example, the cytokines macrophage colony-
stimulating factor and GM-CSF promote the differentiation
of monocytes into macrophages and DCs.4,5 Moreover, in-
vestigations in a mouse model of colitis induced by dextran
sulfate sodium (DSS) have shown that GM-CSF can partially
protect against intestinal inﬂammation, and that GM-CSF-
deﬁcient mice show increased susceptibility to DSS-induced
colitis.5,6 Injection of DSS-colitis mice with GM-CSF was
shown to trigger the accumulation of splenic CD11bþ cells,
which promote wound healing and epithelial cell prolifera-
tion and thereby reduce disease severity. More importantly,
GM-CSF was found to promote clinical responses in patients
with active Crohn’s disease. However, the full action mecha-
nism of GM-CSF, and especially whether monocytes mediate
its effects in vivo, had not been previously elucidated.
In their elegant study, Weinhage et al1 activated bone-
marrow-derived monocytes with GM-CSF in vitro. After
this GM-CSF treatment, the monocytes were found to
overexpress some surface markers of specialized macro-
phages (eg, CD39, CD73, and CD121b) and some stimulatory
molecules (eg, CD80, CD86, MHCII, and B7-H1) while
showing decreased expression of a marker for alternatively
activated monocytes (fractalkine receptor CX3CR1). In
addition, the authors noted discrepancies in the expression
levels of some M2-polarized markers. Because this expres-
sion proﬁle did not fully recapitulate the previously re-
ported activation stages of monocytes, the authors proposed
that the newly generated monocytes represented a unique
and distinct state of activation. These GM-CSF-activated
monocytes (GMaMs) were also found to be somewhat
unique from a functional point of view. The authors
demonstrated in vitro that this population has a lower ca-
pacity for phagocytosis and adhesion, but triggers increased
generation of reactive oxygen species, which are required
for pathogen clearance. Moreover, after lipopolysaccharide
treatment, proinﬂammatory cytokine production was found
to be higher in GMaMs compared with untreated monocytes.Cellular and Molecular Gastroenterology and Hepatology 2015;1:354–3The authors then tested these GMaMs on the DSS-
induced mouse model of chronic colitis. Importantly,
GMaM-treated mice showed clear improvements in intesti-
nal inﬂammation and lower proinﬂammatory cytokine
expression levels in the distal colon. The authors next
sought to decipher the mechanism by which GMaMs confer
their therapeutic effects on intestinal inﬂammation. They
showed that, compared with control monocytes, the GMaMs
were taken up faster by the intestine and stayed there
longer, especially in the Peyer’s patches.
In addition to these unique migratory features, the
GMaMs increased the accumulation of forkhead box P3 pos-
itive (Foxp3þ) T cells in the lymph follicles when compared
with untreated mice or those treated with nonactivated
monocytes. Importantly, this GMaM-mediated protectionwas
completely abolished in Rag1/mice (which lack all mature
adaptive immune cells). Injection of GMaM was not able to
protect the mice against DSS-induced colitis, indicating that
adaptive immunity is required for the GMaM-mediated pro-
tection against colitis. Furthermore, after T-cell transfer into
Rag1/ mice (another model of chronic colitis; fully T-cell
dependent), subsequent injection of GMaMs had beneﬁcial
effects on colitis and increased the Foxp3þ CD4þ T-cell
population. In an in vitro model in which GMaMs were
cocultured with naive T cells, the authors observed increased
proliferation and differentiation of Foxp3þ regulatory T cells
(Treg) and found that this occurred through a mechanism
that involves the CD39-mediated conversion of ATP into
adenosine (a mechanism that was previously reported to
induce Treg cell differentiation).
Taken together, these important data show that GM-CSF
activates GMaMs, a speciﬁc population of monocytes that
has a protective effect against intestinal inﬂammation. The
beneﬁcial effects of GMaMs are T-cell dependent and involve
the CD39/adenosine-mediated proliferation and differenti-
ation of Foxp3þ Treg cells.
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